Agilent Technologies (NYSE:A) Given New $135.00 Price Target at Barclays

Agilent Technologies (NYSE:A – Get Rating) had its target price lowered by Barclays from $140.00 to $135.00 in a research report report published on Wednesday morning, The Fly reports. Barclays currently has an equal weight rating on the medical research company’s stock.

A number of other equities research analysts also recently issued reports on A. Credit Suisse Group increased their price target on shares of Agilent Technologies from $165.00 to $170.00 and gave the stock an outperform rating in a report on Wednesday, March 1st. StockNews.com started coverage on shares of Agilent Technologies in a research note on Thursday, May 18th. They issued a buy rating on the stock. Finally, Robert W. Baird raised their target price on shares of Agilent Technologies from $170.00 to $174.00 and gave the company an outperform rating in a research note on Wednesday, March 1st. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $151.35.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $120.99 on Wednesday. The company has a quick ratio of 1.53, a current ratio of 2.11 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $35.78 billion, a PE ratio of 27.31, a P/E/G ratio of 1.89 and a beta of 1.03. Agilent Technologies has a twelve month low of $112.52 and a twelve month high of $160.26. The company has a 50-day moving average price of $133.87 and a two-hundred day moving average price of $144.11.

Agilent Technologies (NYSE:A – Get Rating) last announced its quarterly earnings results on Tuesday, May 23rd. The medical research company reported $1.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.01. Agilent Technologies had a net margin of 19.09% and a return on equity of 30.35%. The firm had revenue of $1.72 billion for the quarter, compared to the consensus estimate of $1.67 billion. During the same period in the prior year, the firm posted $1.13 earnings per share. The company’s revenue for the quarter was up 6.8% on a year-over-year basis. Equities analysts forecast that Agilent Technologies will post 5.68 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 26th. Stockholders of record on Monday, July 3rd will be issued a $0.225 dividend. This represents a $0.90 annualized dividend and a dividend yield of 0.74%. The ex-dividend date is Friday, June 30th. Agilent Technologies’s dividend payout ratio is 20.32%.

Institutional Trading of Agilent Technologies

Several large investors have recently added to or reduced their stakes in A. Norges Bank bought a new stake in Agilent Technologies in the fourth quarter valued at $393,291,000. BlueSpruce Investments LP purchased a new position in Agilent Technologies during the third quarter valued at $223,829,000. Morgan Stanley lifted its position in Agilent Technologies by 79.4% during the fourth quarter. Morgan Stanley now owns 4,145,767 shares of the medical research company’s stock valued at $620,414,000 after buying an additional 1,835,413 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Agilent Technologies by 22.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,707,052 shares of the medical research company’s stock valued at $1,153,360,000 after buying an additional 1,392,128 shares during the period. Finally, Liontrust Investment Partners LLP purchased a new position in Agilent Technologies during the third quarter valued at $127,895,000.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.